Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) are two major types of Lipid-based nanoparticles.

Jan 21, 2009 · Solid lipid nanoparticles (SLN) are distinguishable from nanostructured lipid carriers (NLC) by the composition of the solid particle matrix. Both are an alternative carrier system to liposomes and emulsions. This review paper focuses on …

Lipid nanoparticles (LN) are recognized as promising drug delivery systems (DDS) in treating skin disorders. Solid lipid nanoparticles (SLN) together with nanostructured lipid carriers (NLC) exhibit excellent tolerability as these are produced from physiological and biodegradable lipids.

Nov 1, 2002 · Solid lipid nanoparticles (SLN) were developed at the beginning of the 1990s as an alternative carrier system to emulsions, liposomes and polymeric nanoparticles. The paper reviews advantages—also potential limitations—of SLN for the use in topical cosmetic and pharmaceutical formulations.

Solid lipid nanoparticles (SLNs) are the first generation of lipid-based nanocarriers that are formulated from lipids, which are solid in the body temperature and stabilized by emulsifiers (1). SLNs have submicron (less than 1000 nm) sizes (9).

We discuss the selection criteria for lipids, surfactants, and surface modifiers commonly in use in SLN/NLC, their production techniques, and the range of drugs loaded in these lipid nanoparticles for the treatment of skin disorders.

This review provides an overview on the current state-of-art of SLN and NLC particularly for cosmetic and dermocosmetic purposes, discuss their formulation composition, structures and preparation techniques.

Jan 21, 2009 · Solid lipid nanoparticles (SLN) are distinguishable from nanostructured lipid carriers (NLC) by the composition of the solid particle matrix. Both are an alternative carrier system to liposomes and emulsions. This review paper focuses on …

May 25, 2023 · SLNs are solid colloidal particles in the sub-micron range, ranging from 4 to 1000 nm, and contain in their formulation physiological, biodegradable, and biocompatible lipids and surfactants, which can incorporate both lipophilic and hydrophilic drugs inside the lipid matrix.

lipid nanoparticles containing SLN and NLC to treat pulmonary disorders. When it comes to treating pulmonary artery disease, for example, phosphodiesterase type 5 inhibitors like sildenafil citrate play a crucial role. With an encapsulation effectiveness ranging from 88% to 100%, these nanoparticles have demonstrated a drug